Key clinical point: Patients with higher platelet lymphocyte ratio (PLR) or C-reactive protein (CRP) levels were more likely to be diagnosed with psoriatic arthritis (PsA) than psoriasis vulgaris (PsV), with patients having higher pretreatment systemic inflammatory marker scores showing lower treatment persistence with conventional therapies.
Major finding: PLR (odds ratio [OR] 7.027; P = .040) or CRP levels (OR 3.179; P = .022) at the time of initial presentation were associated with a higher probability of PsA vs PsV diagnosis, with patients having higher pretreatment platelet or neutrophil counts, PLR, and systemic immune/inflammation index scores exhibiting lower treatment continuation rates for conventional systemic agents (all P < .05).
Study details: Findings are from a retrospective analysis including patients with PsA (n = 47) and PsV (n = 117) and control individuals with no history of allergy or skin diseases (n = 50).
Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.
Source: Sugimoto E, Matsuda H, et al. Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: A retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023;12(8):3046 (Apr 21). Doi: 10.3390/jcm12083046